Comparison between magnesium sulphate and lignocaine for preventing stress on heart during laryngoscopy and endotracheal intubation in patients undergoing surgeries under general anesthesia

Comparison of intravenous magnesium sulphate and intravenous lignocaine for attenuation of cardiovascular response to laryngoscopy and endotracheal intubation in patients undergoing elective surgeries under general anaesthesia - A one year hospital based double blinded Randomised Clinical Trial - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058354

Enrollment

102

Registered

2023-10-05

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Intravenous Magnesium Sulphate: Intravenous Magnesium Sulphate 50%, 30mg/kg slow intravenous stat, 3 min before intubation, vitals from time of intubation upto 10 min Control Interventi

Eligibility

Inclusion criteria

Inclusion criteria: 1. ASA physical status I and II 2. Patients undergoing elective surgeries under general anesthesia 3. Patients providing consent

Exclusion criteria

Exclusion criteria: 1. Patients allergic to drugs under study 2. Patients with contraindication to general anesthesia 3. Patient refusal or who are unable to give consent 4. Patients undergoing emergency surgeries 5. Patients with significant cardiac and respiratory diseases 6. Patients with difficult airway 7. Pregnancy 8. Patients with oral and nasal pathology

Design outcomes

Primary

Measure	Time frame
To compare intravenous lignocaine with intravenous magnesium sulphate with respect to: Hemodynamic variables - Mean arterial pressure, Systolic blood pressure, Diastolic blood pressure, Heart rateTimepoint: At baseline (before intubation), and at 1 min, 2 min, 3 min, 4min, 5min, 7 min, 10 min after intubation	—

Secondary

Measure	Time frame
Incidence of side effects & complications if any of the study drugsTimepoint: From the time of administering the drugs till the end of the surgical procedure	—

Countries

India

Contacts

Public ContactKishore B J

Jawaharlal Nehru Medical College

kedareshvara@gmail.com9886375154

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026